Z Gastroenterol 2006; 44(10): 1053-1063
DOI: 10.1055/s-2006-927005
Übersicht

© Karl Demeter Verlag im Georg Thieme Verlag KG Stuttgart · New York

Neoadjuvante Therapie beim Rektumkarzinom: Auf dem Weg zur individuellen Therapie

Neoadjuvant Treatment of Rectal Cancer: Towards an Individualised TherapyF. Willeke1 , K. Horisberger2 , S. Post2
  • 1Surgery, St.-Marienkrankenhaus Siegen
  • 2Surgery, University Clinic Mannheim
Further Information

Publication History

Manuskript eingetroffen: 13.5.2006

Manuskript akzeptiert: 25.6.2006

Publication Date:
25 October 2006 (online)

Zusammenfassung

Die neoadjuvante Therapie lokal fortgeschrittener Rektumkarzinome ist seit dem Herbst 2004 in die Leitlinien aufgenommen worden. Diese Änderung der Empfehlungen bedeutet einen erheblichen Paradigmenwechsel, da nun die Mehrzahl der behandelten Patienten nicht primär operiert werden sollte. Voraussetzung für eine sinnhafte Therapiestratifizierung ist dabei eine verlässliche Diagnostik. Hier zeichnet sich ab, dass die Kernspintomographie in die Routineabklärung der Patienten mit lokal fortgeschrittenen Rektumkarzinomen aufgenommen wird. Insbesondere die Einschätzung, ob aus einer onkologischen Resektion mit totaler mesorektaler Exzision ein zirkumferenziell tumorfreier Resektionsrand resultiert, gelingt in der MRT zuverlässig und erscheint weniger untersucherabhängig als die Endosonographie. Nicht entschieden ist bisher die Form der neoadjuvanten Therapie. Hier konkurrieren Kurzzeit-Strahlentherapie (5 × 5 Gy) mit Langzeitprotokollen unterschiedlicher Chemotherapiemodifikationen. Letztere werden bei organüberschreitenden Tumoren und distaler Lokalisation eingesetzt, wenn ein Sphinktererhalt ermöglicht werden soll. Chirurgisch-technisch wird eine wissenschaftliche Absicherung der minimalinvasiven Resektion des Rektumkarzinoms erfolgen, der Prämisse eines Sphinktererhaltes um jeden Preis muss eine Auseinandersetzung mit der Sinnhaftigkeit ultratiefer Resektionen folgen. Multimodale Therapien werden aber auch schwierig therapierbare funktionelle Langzeitfolgen nach sich ziehen, die bisher in der Diskussion um eine Verbesserung der onkologischen Ergebnisse unterrepräsentiert sind. Da besonders Patienten von einer Vorbehandlung profitieren, deren Tumoren auch auf eine solche Therapie ansprechen, kommt der Forschung zur Prädiktion der Tumorantwort auf eine neoadjuvante Therapie eine wichtige Rolle zu.

Abstract

Neoadjuvant radiation or chemoradiation followed by oncological resection is the current treatment of choice for locally advanced rectal cancer. Profound diagnostics are mandatory to stratify patients for neoadjuvant treatment or primary surgery. Here, magnetic resonance tomography most probably will become the standard modality due to its ability to predict involvement of the circumferential resection margin during surgery. While the initiation of chemoradiation in T4 rectal cancer and patients with distal tumours potentially undergoing sphincter-preserving surgery is unequivocal, the treatment of choice for the remaining patients is undecided. Here, short-term radiotherapy (5 × 5 Gy) competes with chemoradiation of different intensity. In surgical oncology, minimally invasive surgery of the rectum needs further evidence before it can be accepted as an equivalent. Finally, the increase in multimodality treatment will ultimately increase the incidence of late functional sequelae which, up to now, are underrepresented in most reports due to the priority of oncological results. Since responders to neoadjuvant treatment are the ones who benefit most from these therapies, research related to prediction of treatment response has a fundamental role.

Literatur

  • 1 Schmiegel W, Pox C, Adler G. et al . Novel Guidelines Colorectal Cancer 2004.  Z Gastroenterol. 2004;  42 1129-1177
  • 2 Sauer R, Becker H, Hohenberger W. et al . Preoperative versus postoperative chemoradiotherapy for rectal cancer.  N Engl J Med. 2004;  351 1731-1740
  • 3 Lamberti C, Lundin S, Bogdanow M. et al . Adjuvant and palliative chemotherapy of colorectal cancer in Germany outside controlled trials.  Dtsch Med Wochenschr. 2006;  131 485-490
  • 4 Badea R, Badea G, Philippi W. et al . The value and limits of endorectal sonography in the preoperative stage classification of rectal cancer.  Ultraschall in Med. 1988;  9 265-269
  • 5 Dershaw D D. Endorectal sonography for rectal carcinoma.  Bull N Y Acad Med. 1992;  68 411-419
  • 6 Gavioli M, Bagni A, Piccagli I. et al . Usefulness of endorectal ultrasound after preoperative radiotherapy in rectal cancer: comparison between sonographic and histopathologic changes.  Dis Colon Rectum. 2000;  43 1075-1083
  • 7 Glaser F, Schlag P, Herfarth C. Endorectal ultrasonography for the assessment of invasion of rectal tumours and lymph node involvement.  Br J Surg. 1990;  77 883-887
  • 8 Glaser F, Friedl P, von Ditfurth B. et al . Influence of endorectal ultrasound on surgical treatment of rectal cancer.  Eur J Surg Oncol. 1990;  16 304-311
  • 9 Sunouchi K, Sakaguchi M, Higuchi Y. et al . Small spot sign of rectal carcinoma by endorectal ultrasonography: histologic relation and clinical impact on postoperative recurrence.  Dis Colon Rectum. 1998;  41 649-653
  • 10 Solomon M J, McLeod R S. Endoluminal transrectal ultrasonography: accuracy, reliability, and validity.  Dis Colon Rectum. 1993;  36 200-205
  • 11 Beets-Tan R G, Beets G L. Rectal cancer: how accurate can imaging predict the T stage and the circumferential resection margin?.  Int J Colorectal Dis. 2003;  18 385-391
  • 12 Chan T W, Kressel H Y, Milestone B. et al . Rectal carcinoma: staging at MR imaging with endorectal surface coil. Work in progress.  Radiology. 1991;  181 (2) 461-467
  • 13 Gualdi G F, Casciani E, Guadalaxara A. et al . Local staging of rectal cancer with transrectal ultrasound and endorectal magnetic resonance imaging: comparison with histologic findings.  Dis Colon Rectum. 2000;  43 338-345
  • 14 Beets-Tan R G, Beets G L, Vliegen R F. et al . Accuracy of magnetic resonance imaging in prediction of tumour-free resection margin in rectal cancer surgery.  Lancet. 2001;  357 (9255) 497-504
  • 15 Heindel W, Gossmann A, Schäfer H. et al . Endorectal MRI and ultrasonography in rectal tumors: correlation with histological staging.  Fortschr Röntgenstr. 1998;  168 573-579
  • 16 Hünerbein M, Pegios W, Rau B. et al . Prospective comparison of endorectal ultrasound, three-dimensional endorectal ultrasound, and endorectal MRI in the preoperative evaluation of rectal tumors. Preliminary results.  Surg Endosc. 2000;  14 1005-1009
  • 17 Joosten F B, Jansen J B, Joosten H J. et al . Staging of rectal carcinoma using MR double surface coil, MR endorectal coil, and intrarectal ultrasound: correlation with histopathologic findings.  J Comput Assist Tomogr. 1995;  19 752-758
  • 18 Maldjian C, Smith R, Kilger A. et al . Endorectal surface coil MR imaging as a staging technique for rectal carcinoma: a comparison study to rectal endosonography.  Abdom Imaging. 2000;  25 75-80
  • 19 Nagtegaal I D, Marijnen C AM, Kranenbarg E K. et al . Circumferential margin involvement is still an improtant predictor of local recurrence in rectal carcinoma: not one millimeter but two millimeters is the limit.  Am J Surg Pathol. 2002;  26 350-357
  • 20 Nelson H, Sargent D J. Refining multimodal therapy for rectal cancer.  N Engl J Med. 2001;  345 690-692
  • 21 Radcliffe A G, Brown G. Will MRI provide maps of lines of excision for rectal cancer?.  Lancet. 2001;  357 495-496
  • 22 Ptok H, Marusch F, Meyer F. et al . Feasibility and accuracy of TRUS in the pre-treatment staging for rectal carcinoma in general practice.  Eur J Surg Oncol. 2006;  in press
  • 23 Gerard A, Buyse M, Nordlinger B. et al . Preoperative radiotherapy as adjuvant treatment in rectal cancer. Final results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC).  Ann Surg. 1988;  208 606-614
  • 24 Dahl O, Horn A, Morild I. et al . Low-dose preoperative radiation postpones recurrences in operable rectal cancer. Results of a randomized multicenter trial in western Norway.  Cancer. 1990;  66 2286-2294
  • 25 Cedermark B, Johansson H, Rutqvist L E. et al . The Stockholm I trial of preoperative short term radiotherapy in operable rectal carcinoma. A prospective randomized trial. Stockholm Colorectal Cancer Study Group.  Cancer. 1995;  75 2269-2275
  • 26 Goldberg S, Klas J V. Total mesorectal excision in the treatment of rectal cancer: a view from the USA.  Semin Surg Oncol. 1998;  15 87-90
  • 27 Marsh P J, James R D, Schofield P F. Adjuvant preoperative radiotherapy for locally advanced rectal carcinoma. Results of a prospective, randomized trial.  Dis Colon Rectum. 1994;  37 1205-1214
  • 28 Randomised trial of surgery alone versus surgery followed by radiotherapy for mobile cancer of the rectum. Medical Research Council Rectal Cancer Working Party (see comments).  Lancet. 1996;  348 (9042) 1610-1614
  • 29 Holm T, Johansson H, Rutqvist L E. et al . Tumour location and the effects of preoperative radiotherapy in the treatment of rectal cancer.  Br J Surg. 2001;  88 839-843
  • 30 Kapiteijn E, Marijnen C AM, Nagtegaal I D. et al . Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.  N Engl J Med. 2001;  345 638-646
  • 31 Randomized study on preoperative radiotherapy in rectal carcinoma. Stockholm Colorectal Cancer Study Group (see comments).  Ann Surg Oncol. 1996;  3 423-430
  • 32 Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial.  N Engl J Med. 1997;  336 980-987
  • 33 Marijnen C AM, Nagtegaal I D, Kranenbarg E K. et al . No downstaging after short-term preoperative radiotherapy in rectal cancer patients.  J Clin Oncol. 2001;  19 1976-1984
  • 34 Birgisson H, Pahlman L, Gunnarsson U. et al . Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish Rectal Cancer Trial.  J Clin Oncol. 2005;  23 8697-8705
  • 35 Peeters K CMJ, van de Velde C JH, Leer J WH. et al . Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients - A Dutch Colorectal Cancer Group Study.  J Clin Oncol. 2005;  23 6199-6206
  • 36 Marijnen C AM, van de Velde C J. et al . Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: Report of a multicenter randomized trial.  J Clin Oncol. 2005;  23 1847-1858
  • 37 Marijnen C AM, Kapiteijn E, van de Velde C J. et al . Acute side effects and complications after short-term preoperative radiotherapy combined with total mesorectal excision in primary rectal cancer: Report of a multicenter randomized trial.  J Clin Oncol. 2000;  20 817-825
  • 38 Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy (see comments).  Int J Colorectal Dis. 1997;  12 19-23
  • 39 Gavioli M, Luppi G, Losi L. et al . Incidence and clinical impact of sterilized disease and minimal residual disease after preoperative radiochemotherapy for rectal cancer.  Dis Colon Rectum. 2005;  48 1851-1857
  • 40 Rödel C, Martus P, Papadoupoulos T. et al . Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.  J Clin Oncol. 2005;  23 8688-8696
  • 41 Pucciarelli S, Toppan P, Friso M L. et al . Complete pathologic response following preoperative chemoradiation therapy for middle to lower rectal cancer is not a prognostic factor for a better outcome.  Dis Colon Rectum. 2004;  47 1798-1807
  • 42 Chan A, Wong A, Langevin J. et al . Preoperative concurrent 5-fluorouracil infusion, mitomycin C and pelvic radiation therapy in tethered and fixed rectal carcinoma (see comments).  Int J Radiat Oncol Biol Phys. 1993;  25 791-799
  • 43 Keilholz L, Sauer R. Adjuvant radiochemotherapy of rectal carcinoma.  Schweiz Rundsch Med Prax. 1995;  84 1377-82
  • 44 Luna-Perez P, Rodriguez-Ramirez S, Rodriguez-Coria D. et al . Preoperative chemoradiation therapy and anal sphincter preservation with locally advanced rectal adenocarcinoma.  World J Surg. 2001;  25 1006-1011
  • 45 Mehta V K, Poen J, Ford J. et al . Radiotherapy, concomitant protracted-venous-infusion 5-fluorouracil, and surgery for ultrasound-staged T3 or T4 rectal cancer.  Dis Colon Rectum. 2001;  44 52-58
  • 46 Rullier E, Goffre B, Bonnel C. et al . Preoperative radiochemotherapy and sphincter-saving resection for T3 carcinomas of the lower third of the rectum.  Ann Surg. 2001;  234 633-640
  • 47 Rich T A, Skibber J M, Ajani J A. et al . Preoperative infusional chemoradiation therapy for stage T3 rectal cancer.  Int J Radiat Oncol Biol Phys. 1995;  32 1025-1029
  • 48 Movsas B, Hanlon A L, Lanciano R. et al . Phase I dose escalating trial of hyperfractionated pre-operative chemoradiation for locally advanced rectal cancer.  Int J Radiat Oncol Biol Phys. 1998;  42 43-50
  • 49 Rödel C, Grabenbauer G G, Matzel K E. et al . Extensive surgery after high-dose preoperative chemoradiotherapy for locally advanced recurrent rectal cancer.  Dis Colon Rectum. 2000;  43 312-319
  • 50 Tjandra J J, Reading D M, McLachlan S A. et al . Phase II clinical trial of preoperative combined chemoradiation for T3 and T4 resectable rectal cancer: preliminary results.  Dis Colon Rectum. 2001;  44 1113-1122
  • 51 Rau B, Hohenberger P, Gellermann J. et al . T4 rectal carcinoma. Surgical and multimodal therapy.  Chirurg. 2002;  73 147-153
  • 52 Quirke P. Training and quality assurance for rectal cancer: 20 years of data is enough.  Lancet Oncol. 2003;  4 695-702
  • 53 Brown G, Daniels I R. Preoperative staging of rectal cancer: the MERCURY research project.  Recent Results Cancer Res. 2005;  165 58-74
  • 54 Kim J S, Kim J S, Cho M J. et al . Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer.  Int J Radiat Oncol Biol Phys. 2002;  54 403-408
  • 55 Kim J C, Kim T W, Kim J H. et al . Preoperative concurrent radiotherapy with capecitabine before total mesorectal excision in locally advanced rectal cancer.  Int J Radiat Oncol Biol Phys. 2005;  63 346-353
  • 56 De Paoli A, Chiara S, Luppi G. et al . Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study.  Ann Oncol. 2006;  17 246-251
  • 57 Kim N K, Min J S, Park J K. et al . Intravenous 5-fluorouracil versus oral doxifluridine as preoperative concurrent chemoradiation for locally advanced rectal cancer: prospective randomized trials.  Jpn J Clin Oncol. 2001;  31 25-29
  • 58 Ngan S Y, Michael M, Mackay J. et al . A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer.  Br J Cancer. 2004;  91 1019-1024
  • 59 Gerard J P, Chapet O, Nemoz C. et al . Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R0 - 04 phase II trial.  J Clin Oncol. 2003;  21 1119-1124
  • 60 Hofheinz R D, von Gerstenberg-Helldorf B, Wenz F. et al . Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer.  J Clin Oncol. 2005;  23 1350-1357
  • 61 Klautke G, Feyerherd P, Ludwig K. et al . Intensified concurrent chemoradiotherapy with 5-fluorouracil and irinotecan as neoadjuvant treatment in patients with locally advanced rectal cancer.  Br J Cancer. 2005;  92 1215-1220
  • 62 Sebag-Montefiore D, Glynne-Jones R, Falk S. et al . A phase I/II study of oxaliplatin when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group (CCOG) study.  Br J Cancer. 2005;  93 993-998
  • 63 Chau I, Brown G, Cunningham D. et al . Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer.  J Clin Oncol. 2006;  24 668-6674
  • 64 Mohiuddin M, Winter K, Mitchell E. et al . Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012.  J Clin Oncol. 2006;  24 650-655
  • 65 Mitchell E P. Irinotecan in preoperative combined-modality therapy for locally advanced rectal cancer.  Oncology (Williston Park). 2000;  14 (12, Suppl 14) 56-59
  • 66 Francois E, Ychou M, Ducreux M. et al . Combined radiotherapy, 5-fluorouracil continuous infusion and weekly oxaliplatin in advanced rectal cancer: a phase I study.  Eur J Cancer. 2005;  41 2861-2867
  • 67 Mehta V K, Cho C, Ford J M. et al . Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer.  Int J Radiat Oncol Biol Phys. 2003;  55 132-137
  • 68 Rödel C, Grabenbauer G G, Papadopoulos T. et al . Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer.  J Clin Oncol. 2003;  21 3098-3104
  • 69 Czito B G, Willett C G, Bendell J C. et al . Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results.  J Clin Oncol. 2006;  24 656-662
  • 70 Peel A LG, Taylor E W. Proposed definitions for the audit of postoperative infection: a discussion paper.  Ann R Coll Surg Engl. 1991;  73 385-388
  • 71 Goligher J C, Dukes C E, Bussey H J. Local recurrence after sphincter saving excisions for carcinoma of the rectum and rectosigmoid.  Br J Surg. 1951;  39 199-203
  • 72 Williams N S, Dixon M F, Johnston D. Reappraisal of the 5 centimetre rule of distal excision for carcinoma of the rectum: a study of distal intramural spread and of patients survival.  Br J Surg. 1983;  70 150-154
  • 73 Pollett W, Nicholls R. The relationship between the extent of distal clearence and survival and local recurrence rates after curative anterior resection for carcinoma of the rectum.  Ann Surg. 1983;  198 159-163
  • 74 Quirke P, Durdey P, Dixon M F. et al . Local recurrence of rectal adenocarcinoma due to inadequate surgical resection: Histopathological study of lateral tumour spread and surgical excision.  Lancet. 1986;  2 996-999
  • 75 Rullier E, Laurent C, Bretagnol F. et al . Sphincter-saving resection for all rectal carcinomas - The end of the 2-cm distal rule.  Ann Surg. 2005;  241 465-469
  • 76 Heald R J, Moran B J, Ryall R D. et al . Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978 - 1997.  Arch Surg. 1998;  133 894-899
  • 77 Havenga K, Enker W E, McDermott K. et al . Male and female sexual and urinary function after total mesorectal excision with autonomic nerve preservation for carcinoma of the rectum.  J Am Coll Surg. 1996;  182 495-502
  • 78 Hermanek P. Impact of surgeon’s technique on outcome after treatment of rectal carcinoma.  Dis Colon Rectum. 1999;  42 559-562
  • 79 Hermanek P, Guggenmoos-Holzmann I, Gall F P. Prognostic factors in rectal carcinoma. A contribution to the further development of tumor classification.  Dis Colon Rectum. 1989;  32 593-599
  • 80 Brown G, Daniels I R. Preoperative staging of rectal cancer: The MERCURY Research Project.  Recent Results Cancer Res. 2005;  165 58-74
  • 81 Hartley J E, Mehigan B J, Qureshi A E. et al . Total mesorectal excision: Assessment of the laparoscopic approach.  Diseases of the Colon & Rectum. 2001;  44 315-321
  • 82 Bruch H P, Herold A, Schiedeck T HK. et al . Laparoscopic surgery for rectal cancer.  Zentralblatt fur Chirurgie. 1997;  122 1134-1141
  • 83 Baker R P, White E E, Titu L. et al . Does laparoscopic abdominoperineal resection of the rectum compromise long-term survival?.  Diseases of the Colon & Rectum. 2002;  45 1481-1485
  • 84 Iroatulam A JN, Agachan F, Alabaz O. et al . Laparoscopic abdominoperineal resection for anorectal cancer.  American Surgeon. 1998;  64 12-18
  • 85 Nagtegaal I D, van de Velde C JH, Marijnen C AM. et al . Low rectal cancer: A call for a change of approach in abdominoperineal resection.  J Clin Oncol. 2005;  23 9257-9264
  • 86 Marr R, Birbeck K F, Garvican J. et al . The modern abdominoperineal excision - the next challenge after total mesorectal excision: A clinical and morphometric study.  Ann Surg. 2005;  242 74-82
  • 87 Habr-Gama A, Perez R O, Nadalin W. et al . Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival.  J Gastrointest Surg. 2005;  9 90-99
  • 88 Habr-Gama A, Perez R O, Kiss D R. et al . Preoperative chemoradiation therapy for low rectal cancer. Impact on downstaging and sphincter-saving operations.  Hepatogastroenterology. 2004;  51 1703-1707
  • 89 Habr-Gama A, Perez R O, Nadalin W. et al . Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.  Ann Surg. 2004;  240 711-717
  • 90 Hiotis S P, Weber S M, Cohen A M. et al . Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: An analysis of 488 patients.  J Am Coll Surg. 2002;  194 131-136
  • 91 Bonnen M, Crane C, Vauthey J. et al . Long term results using local excision after preoperative chemoradiation among selected T3 rectal cancer patients.  Int J Radiat Oncol Biol Phys. 2004;  60 1098-1105
  • 92 Wong C S, Cummings B J, Keane T J. et al . Results of external beam irradiation for rectal carcinomas locally recurrent after local excision or electrocoagulation.  Radiother Oncol. 1991;  22 145-148
  • 93 Garcia-Aguilar J, Mellgren A, Sirivongs P. et al . Local excision of rectal cancer without adjuvant therapy: a word of caution.  Ann Surg. 2000;  231 345-351
  • 94 Taylor R H, Hay J H, Larsson S N. Transanal local excision of selected low rectal cancers.  Am J Surg. 1998;  175 360-363
  • 95 Lundby L, Krogh K, Jensen V J. et al . Long-term anorectal dysfunction after postoperative radiotherapy for rectal cancer.  Dis Colon Rectum. 2005;  48 1343-1349
  • 96 Smith F M, Reynolds J V, Miller N. et al . Pathological and molecular predictors of the response of rectal cancer to neoadjuvant radiochemotherapy.  Eur J Surg Oncol. 2006;  32 55-64

Dr. Frank Willeke

Surgery, St.-Marienkrankenhaus Siegen

Kampenstr. 51

57072 Siegen

Phone: ++49/2 71/2 31 15 00

Fax: ++49/2 71/2 31 15 09

Email: f.willeke@marienkrankenhaus.com

    >